Intravitreal injection

Aerpio Announces First Patient Dosed with Razuprotafib in the Phase 2 Trial for the Prevention and Treatment of ARDS in Patients with Moderate-to-Severe COVID-19

Retrieved on: 
Monday, October 26, 2020
Clinical medicine, Medical specialties, Medicine, Intravitreal administration, Ophthalmic drug administration, Acute respiratory distress syndrome, Intravitreal injection, Coronavirus disease, Macular degeneration, Bispecific monoclonal antibody

We commend our clinical team and the trial investigators who have established a close collaboration in this important program, said Joseph Gardner, President and Founder of Aerpio.

Key Points: 
  • We commend our clinical team and the trial investigators who have established a close collaboration in this important program, said Joseph Gardner, President and Founder of Aerpio.
  • Additionally, therapeutics that can prevent or treat ARDS in COVID-19 may prove useful in other diseases where ARDS is the primary cause of morbidity and mortality.
  • This bispecific antibody has the potential to be an improved treatment for wet age-related macular degeneration and DME via intravitreal injection.
  • In addition, a subcutaneous formulation of razuprotafib is being explored for its therapeutic potential in treating or preventing ARDS associated with COVID-19.